Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID‐19: a rapid review and meta‐analysis
This study aimed to examine the efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for
coronavirus disease 2019 (COVID‐19). PubMed, Cochrane Library, Web of Science …
coronavirus disease 2019 (COVID‐19). PubMed, Cochrane Library, Web of Science …
Oral antiviral treatment for COVID-19: a comprehensive review on nirmatrelvir/ritonavir
Despite the rapid development of efficient and safe vaccines against COVID-19, the need to
confine the pandemic and treat infected individuals on an outpatient basis has led to the …
confine the pandemic and treat infected individuals on an outpatient basis has led to the …
Effectiveness of molnupiravir and nirmatrelvir–ritonavir in hospitalized patients with COVID-19: a target trial emulation study
Background: Whether hospitalized patients benefit from COVID-19 oral antivirals is
uncertain. Objective: To examine the real-world effectiveness of molnupiravir and …
uncertain. Objective: To examine the real-world effectiveness of molnupiravir and …
Key considerations during the transition from the acute phase of the COVID-19 pandemic: a narrative review
P Rzymski, M Pokorska-Śpiewak, T Jackowska… - Vaccines, 2023 - mdpi.com
The COVID-19 pandemic has been met with an unprecedented response from the scientific
community, leading to the development, investigation, and authorization of vaccines and …
community, leading to the development, investigation, and authorization of vaccines and …
Nirmatrelvir–ritonavir for the treatment of COVID‐19 patients: A systematic review and meta‐analysis.
The landscape of development of treatment modalities and preventive measures for COVID-
19 has progressed expeditiously since the beginning of the pandemic. We included all the …
19 has progressed expeditiously since the beginning of the pandemic. We included all the …
Drug treatment of COVID-19 infection
G Lui, G Guaraldi - Current opinion in pulmonary medicine, 2023 - journals.lww.com
Drug treatment of COVID-19 infection : Current Opinion in Pulmonary Medicine Drug treatment
of COVID-19 infection : Current Opinion in Pulmonary Medicine Log in or Register Subscribe to …
of COVID-19 infection : Current Opinion in Pulmonary Medicine Log in or Register Subscribe to …
Real-world effectiveness of nirmatrelvir/ritonavir against COVID-19 hospitalizations and severe COVID-19 in community-dwelling elderly Singaporeans during …
LE Wee, AT Tay, C Chiew, BE Young, B Wong… - Clinical Microbiology …, 2023 - Elsevier
Objectives Real-world data on continued effectiveness of nirmatrelvir/ritonavir against
hospitalization and severe COVID-19 in the context of widespread booster mRNA vaccine …
hospitalization and severe COVID-19 in the context of widespread booster mRNA vaccine …
Association of nirmatrelvir for acute SARS‐CoV‐2 infection with subsequent Long COVID symptoms in an observational cohort study
MS Durstenfeld, MJ Peluso, F Lin… - Journal of Medical …, 2024 - Wiley Online Library
Oral nirmatrelvir/ritonavir is approved as treatment for acute COVID‐19, but the effect of
treatment during acute infection on risk of Long COVID is unknown. We hypothesized that …
treatment during acute infection on risk of Long COVID is unknown. We hypothesized that …
Comparative efficacy and safety of nirmatrelvir/ritonavir and molnupiravir for COVID‐19: A systematic review and meta‐analysis
This study aimed to compare the efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) with
molnupiravir in the treatment of coronavirus disease 2019 (COVID‐19). To end this …
molnupiravir in the treatment of coronavirus disease 2019 (COVID‐19). To end this …
Efficacy of nirmatrelvir and ritonavir for post‐acute COVID‐19 sequelae beyond 3 months of SARS‐CoV‐2 infection
The effect of nirmatrelvir plus ritonavir (NMV‐r) on post‐acute COVID‐19 sequelae beyond 3
months of SARS‐CoV‐2 infection remains unknown. This retrospective cohort study utilized …
months of SARS‐CoV‐2 infection remains unknown. This retrospective cohort study utilized …